Pharvaris N.V. (NASDAQ:PHVS) Stock Has Average Price Target of $59.53 According to Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and fourteen have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $59.53.

Several brokerages have commented on PHVS. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Pharvaris in a research note on Monday, September 14th. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating on shares of Pharvaris in a report on Friday. New Street Research set a $60.00 price objective on shares of Pharvaris in a research report on Friday, August 14th. Finally, Leerink Partners upped their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th.

Pharvaris Stock Up 2.4%

Shares of Pharvaris stock opened at $31.41 on Friday. Pharvaris has a 12 month low of $21.02 and a 12 month high of $43.25. The business has a fifty day simple moving average of $33.98 and a 200 day simple moving average of $32.52. The stock has a market cap of $2.05 billion, a PE ratio of -10.30 and a beta of -2.46.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts expect that Pharvaris will post -3.12 EPS for the current fiscal year.

Insider Activity at Pharvaris

In related news, President Peng Lu sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the completion of the sale, the president directly owned 64,953 shares of the company’s stock, valued at approximately $2,273,355. This represents a 60.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elisabeth Bjork sold 52,500 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the sale, the director directly owned 15,167 shares of the company’s stock, valued at approximately $574,677.63. The trade was a 77.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 513,102 shares of company stock valued at $18,643,666 over the last 90 days. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. Quantbot Technologies LP bought a new position in Pharvaris during the 2nd quarter worth about $41,000. CoreCap Advisors LLC bought a new stake in shares of Pharvaris in the second quarter valued at about $93,000. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris during the second quarter worth about $196,000. Algert Global LLC acquired a new position in shares of Pharvaris during the second quarter worth about $238,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Pharvaris during the second quarter worth about $273,000.

About Pharvaris

Pharvaris N.V. (NASDAQ: PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris’ lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.